Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 7/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | G6PD | P11413 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | GSTA2 | P09210 | 2/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | GSTM1 | P09488 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21853584 | 0.73 | GSTP1 (0.54) | GSTP1ALDH1A1CYP3A4NLRP3KDM4E | |
| SCHEMBL10824824 | 0.70 | GSTP1 (0.68) | GSTP1ALDH1A1CYP3A4MAPTNLRP3 | |
| SCHEMBL1141683 | 0.69 | ALDH1A1 (0.47) | GSTP1ALDH1A1CYP3A4SMN1; SMN2NLRP3 | |
| SCHEMBL12288881 | 0.69 | PTPN1 (0.40) | ALDH1A1CYP3A4CYP19A1 | |
| SCHEMBL13034173 | 0.65 | RXRA (0.47) | ALDH1A1CYP3A4 | |
| SCHEMBL8061402 | 0.65 | ALDH1A1 (0.43) | GSTP1ALDH1A1CYP3A4NLRP3KDM4E | |
| SCHEMBL23544215 | 0.63 | ALDH1A1 (0.38) | GSTP1ALDH1A1CYP3A4NLRP3KDM4E | |
| SCHEMBL14855693 | 0.63 | — | — | |
| SCHEMBL20959823 | 0.62 | ALDH1A1 (0.45) | GSTP1ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL13034154 | 0.62 | MEN1 (0.48) | ALDH1A1CYP3A4SMN1; SMN2KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11065235-B2 | Substituted methanopyrido [2, 1-a] isoindolones as mAChR modulators for treating various associated pathophysiological conditions and process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-07-20 | — | — | US | disclosed |
| US-20200121657-A1 | SUBSTITUTED METHANOPYRIDO [2, 1-a] ISOINDOLONES AS mAChR MODULATORS FOR TREATING VARIOUS ASSOCIATED PATHOPHYSIOLOGICAL CONDITIONS AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121657-A1 | SUBSTITUTED METHANOPYRIDO [2, 1-a] ISOINDOLONES AS mAChR MODULATORS FOR TREATING VARIOUS ASSOCIATED PATHOPHYSIOLOGICAL CONDITIONS AND PROCESS FOR PREPARATION THEREOF | CHRM3, CHRM5, ADRB1 | GSTP1 911/4885ALDH1A1 888/4885CYP3A4 154/4885 |
| US-11065235-B2 | Substituted methanopyrido [2, 1-a] isoindolones as mAChR modulators for treating various associated pathophysiological conditions and process for preparation thereof | CHRM1, CHRM3, CHRM5 | GSTP1 1055/4885ALDH1A1 738/4885CYP3A4 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.